A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
AstraZeneca
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Alabama at Birmingham
Dana-Farber Cancer Institute
University of Alabama at Birmingham
National Cancer Institute (NCI)